Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Attention-Deficit Hyperactivity Disorder (ADHD). Sold as Qelbree. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Viloxazine Hydrochloride (sold as Qelbree), first approved Apr 2, 2021, with 1 new use approved and 1 published complete response letter.
First approved: Apr 2, 2021
Applications: 3
New uses approved: 1
Complete response letters: 1
Medicare spending, 2025: $9.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Qelbree
Part D
$9.9M
+46%
4,019
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
QELBREE ER 100 MG CAPSULE: $12.73 per unitBrand · +6% in a year
QELBREE ER 150 MG CAPSULE: $12.73 per unitBrand · +6% in a year
QELBREE ER 200 MG CAPSULE: $12.73 per unitBrand · +6% in a year
Clinical Trials
4 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
